for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cansino Biologics Inc

6185.HK

Latest Trade

170.50HKD

Change

-12.50(-6.83%)

Volume

1,911,767

Today's Range

168.80

 - 

183.80

52 Week Range

35.00

 - 

285.80

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
183.00
Open
181.00
Volume
1,911,767
3M AVG Volume
33.67
Today's High
183.80
Today's Low
168.80
52 Week High
285.80
52 Week Low
35.00
Shares Out (MIL)
264.17
Market Cap (MIL)
74,804.38
Forward P/E
--
Dividend (Yield %)
--

Next Event

Cansino Biologics Inc Annual Shareholders Meeting

Latest Developments

More

Solution Group Says Unit Signed Commercialisation Agreement With Cansino Biologics

Cansino Biologics Initiated Enrollment Of Phase III Clinical Trial For Ad5-nCoV In Russia

Cansino Biologics Clarifies Collaboration Between Canada's Research Council & Co Has Not Been Terminated

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cansino Biologics Inc

CanSino Biologics Inc is a clinical-stage vaccine company in China. The Company's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.

Industry

Biotechnology & Drugs

Contact Info

+86.22.58213600

http://www.cansinotech.com.cn/

Executive Leadership

Xuefeng Yu

Executive Chairman of the Board, Chief Executive Officer, General Manager

Shou Bai Chao

Chief Operating Officer, Deputy General Manager, Executive Director

Dongxu Qiu

Senior Vice President, Deputy General Manager, Executive Director

Huihua Mao

Senior Vice President, Deputy General Manager

Zhu Tao

Chief Scientific Officer, Deputy General Manager, Executive Director

Key Stats

2.00 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2019

0.0K

2020(E)

0.3K
EPS (CNY)

2019

-0.770

2020(E)

-0.911
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
23.77
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
11.22
LT Debt To Equity (MRQ)
8.36
Return on Investment (TTM)
-11.44
Return on Equity (TTM)
-10.63

Latest News

Latest News

Pakistani doctor urges people to volunteer for COVID-19 vaccine trial

The physician heading a Phase III clinical trial in Pakistan for a Chinese COVID-19 vaccine candidate has urged people to volunteer for the trial, overcoming the resistance in the country to immunisation programmes.

Pakistan launches Phase III trials for Chinese Cansinobio's COVID-19 vaccine

Pakistan has launched Phase III clinical trials for CanSino Biologics' COVID-19 vaccine candidate, a government minister and an official at the Chinese pharmaceutical company said on Tuesday.

Pakistan launches Phase III trials for Chinese company Cansinobio's COVID-19 vaccine

Pakistan has launched Phase III clinical trials for Chinese company Cansinobio's COVID-19 vaccine candidate, a government minister and an official at the pharmaceutical company said on Tuesday.

Chinese researchers to test double doses of CanSino's coronavirus vaccine candidate

Researchers plan to start a clinical trial for an additional dose of a coronavirus vaccine candidate co-developed by China's CanSino Biologics Inc and a military-backed research unit, clinical trial registry data showed.

CanSino Phase 3 COVID-19 vaccine trial in Pakistan expected to begin this month

Falling COVID-19 infection numbers in Pakistan will not affect a Phase 3 clinical trial for a potential vaccine being developed by China's CanSino Biologics, which is expected to begin this month, according to officials running the trial.

China's CanSino defends coronavirus vaccine candidate after experts cast doubt

China's CanSino Biologics Inc said on Wednesday that expert opinion on its high-profile coronavirus vaccine candidate should not be followed "blindly" without sufficient clinical trial data.

China's CanSino defends coronavirus vaccine candidate after experts cast doubt

China's CanSino Biologics Inc said on Wednesday expert opinion on its high-profile coronavirus vaccine candidate should not be followed "blindly" without sufficient clinical trial data.

China says halt of coronavirus vaccine partnership unrelated to Canada relations

China said on Thursday that the end to a partnership on a coronavirus vaccine between Chinese firm CanSino Biologics and Canada is unrelated to diplomatic relations between the countries.

UPDATE 1-Chinese vaccine maker's coronavirus program with Canada ends

Canada's National Research Council (NRC) said on Wednesday that it has ended its partnership for a coronavirus vaccine with CanSino Biologics, saying the Chinese company lacks the authority to ship the vaccine at this time.

CanSino blames Chinese officials for failure of joint vaccine program with Canada: Globe and Mail

Chinese vaccine-maker CanSino Biologics said on Tuesday domestic bureaucratic indecision was the reason behind the failure of a coronavirus vaccine partnership with Canada, the Globe and Mail reported, citing the company's chief executive officer.

Pakistan gives go-ahead to Phase 3 COVID-19 vaccine trial

Pakistan's drug regulator greenlit the country's first Phase 3 clinical trial for a potential COVID-19 vaccine, which is being developed by China's CanSino Biologics (CanSino) and Beijing Institute of Biotechnology.

China's CanSino says hasn't begun enrolling people for Phase 3 trial

China's CanSino Biologics said on Tuesday it had not started enrolling participants for a late-stage trial of its potential COVID-19 vaccine Ad5-nCoV.

Testing of CanSino's COVID-19 candidate vaccine begins in Russia

Russia's Petrovax has started a late-stage trial of a COVID-19 candidate vaccine from CanSino Biologics Inc in the country, records show, as the Chinese drug firm steps up testing abroad to close in on regulatory approval.

Testing of CanSino's COVID-19 candidate vaccine begins in Russia

A late-stage trial of a COVID-19 candidate vaccine from CanSino Biologics Inc has started in Russia, registration records showed, as the Chinese pharmaceutical firm steps up testing abroad to close in on regulatory approval.

China grants country's first COVID-19 vaccine patent to CanSino: state media

China's vaccine specialist CanSino Biologics Inc has won a patent approval from Beijing for its COVID-19 vaccine candidate Ad5-nCOV, state media reported, citing documents from the country's intellectual property regulator.

CanSino to start Phase III trial of COVID-19 vaccine in Saudi

Saudi Arabia will soon begin Phase III clinical trials on around 5,000 people for a COVID-19 vaccine developed by China's CanSino Biologics Inc, a Saudi health ministry spokesman said on Sunday.

CanSino coronavirus vaccine shows immune response in human trial

A vaccine against the coronavirus developed by CanSino Biologics Inc <6185.HK> and China's military research unit appears to be safe and induced immune responses in most subjects in a closely-watched mid-stage study, researchers said on Monday.

CanSino COVID-19 vaccine shows immune response in human trial

A COVID-19 vaccine developed by CanSino Biologics Inc and China's military research unit has shown to be safe and induced immune response in most of the recipients who got one shot, researchers said on Monday.

China's CanSino in talks for COVID-19 vaccine Phase III trial overseas

Chinese vaccine developer CanSino Biologics is in talks with Russia, Brazil, Chile and Saudi Arabia to launch a Phase III trial of its experimental COVID-19 vaccine, its co-founder said on Saturday.

CanSino's COVID-19 vaccine candidate approved for military use in China

China's military has received the greenlight to use a COVID-19 vaccine candidate developed by its research unit and CanSino Biologics <6185.HK> after clinical trials proved it was safe and showed some efficacy, the company said on Monday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up